Hyperglycemic Crises in Adults With Diabetes: A Consensus Report

https://doi.org/10.2337/dci24-0032

The American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), Joint British Diabetes Societies for Inpatient Care (JBDS), American Association of Clinical Endocrinology (AACE), and Diabetes Technology Society (DTS) convened a panel of internists and diabetologists to update the ADA consensus statement on hyperglycemic crises in adults with diabetes, published in 2001 and last updated in 2009. The objective of this consensus report is to provide up-to-date knowledge about the epidemiology, pathophysiology, clinical presentation, and recommendations for the diagnosis, treatment, and prevention of diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) in adults. A systematic examination of publications since 2009 informed new recommendations. The target audience is the full spectrum of diabetes health care professionals and individuals with diabetes.

Diabetic ketoacidosis (DKA) and the hyperglycemic hyperosmolar state (HHS) are the two most serious, acute, and life-threatening hyperglycemic emergencies in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) (1–3). Global reports clearly show an increase in the number of DKA and HHS admissions during the past decade, with recent data reporting a 55% increase in the rate of DKA hospitalizations, especially in adults aged <45 years (4–6). DKA is characterized by the triad of hyperglycemia, increased ketone concentration in the blood and/or urine, and metabolic acidosis, while HHS is characterized by severe hyperglycemia, hyperosmolality, and dehydration in the absence of significant ketosis or acidosis. The metabolic derangements in DKA result from the combination of absolute or relative insulin deficiency (levels insufficient to suppress gluconeogenesis and ketone production) and elevation of counterregulatory hormones (glucagon, epinephrine, norepinephrine, cortisol, and growth hormone) (1,3,7). In HHS, there is a residual amount of insulin secretion that minimizes ketosis but does not control hyperglycemia (1,3).

Both DKA and HHS can occur at any age in people with T1D, T2D, or any other type of diabetes. DKA is more common in young people with T1D, and HHS is more frequently reported in older adults with T2D. Although any acute illness or physiological stress can precipitate DKA and HHS, the most frequent causes are infection, particularly urinary tract infections and pneumonia, and the omission of insulin therapy. In recent years, sodium–glucose cotransporter 2 (SGLT2) inhibitors have been found to increase the risk of DKA, most often when used in T1D but also in T2D (2). The incidence of both DKA and HHS was reported to have increased during the COVID-19 pandemic (8,9). Early diagnosis and management of DKA and HHS are essential to improve outcomes. The mainstays of treatment of DKA and HHS are fluid replacement, insulin therapy, electrolyte repletion, and treatment of obesity and diabetes.
underlying precipitating events. Appropriate treatment has reduced mortality owing to DKA to <1%; however, mortality has remained 5- to 10-fold higher in individuals with HHS (1,10).

The objective of this consensus report is to provide up-to-date knowledge about the epidemiology, pathophysiology, clinical presentation, and recommendations for the diagnosis, treatment, and prevention of DKA and HHS in adults. The target audience is the full spectrum of diabetes health care professionals and individuals with diabetes.

RESEARCH DESIGN AND METHODS

This consensus report is an update of the American Diabetes Association (ADA) consensus statement on hyperglycemic crises in adults with diabetes, published in 2001 and last updated in 2009 (11,12). The ADA convened a panel of internists and diabetologists representing the ADA, European Association for the Study of Diabetes (EASD), Joint British Diabetes Societies for Inpatient Care (JBDS), American Association of Clinical Endocrinology (AACE), and Diabetes Technology Society (DTS).

At the beginning of the writing process, all members of the expert panel participated in a day-long virtual meeting and agreed on the direction for this consensus report, the methodology and rigor to be followed for this report, and the established writing teams to author the various sections of the report. The writing group, with the help of a methodologist, conducted comprehensive literature searches in PubMed using medical subject headings to identify human studies published in English between 1 January 2009 and 1 June 2023. To identify contemporary evidence, they included information from observational studies, randomized controlled trials, and systematic reviews. Monthly calls were held between October 2022 and September 2023, with additional email and web-based collaboration. One in-person meeting was conducted to provide organization to the process, establish the review process, reach consensus on the content and key definitions, and discuss the recommendations. Once the draft was completed, the structured peer review process was implemented, and the report was sent to external peer reviewers and respective committees of all the contributing organizations. A final draft was completed and submitted to all five organizations for final review and approval. The guidance represents the panel’s collective analysis, evaluation, and expert opinion.

Questions related to clinical practice provide the framework for this update on hyperglycemic crises in adults. This update includes eight sections that cover new evidence about epidemiology, pathogenesis, diagnostic criteria, recommended treatment, complications during treatment, management in special populations, prevention, and priority areas for future research.

Section 1. What Are Recent Global Trends in Epidemiology and Outcomes?

Nearly 1% of all hospitalizations in people with diabetes are for hyperglycemic crises. However, estimates vary widely among studies because of different populations, settings, types of events captured, and methods of event ascertainment. In a U.S.-based study, 38% of hospital admissions for hyperglycemic crises were for DKA, 35% for HHS, and 27% for mixed DKA/HHS (10). Most DKA events occur in young adults aged 18–44 years (61.7%) with T1D (70.6%), while HHS events are more common among middle-aged adults 45–64 years (47.5%) with T2D (88.1%) (13). Additionally, several studies have revealed that over half of Black/African American and Hispanic/Latino adults with newly diagnosed diabetes presenting with unprovoked DKA have T2D (14–16). The clinical presentation in such cases is acute, as in classical DKA observed in people with T1D; however, after immediate stabilization and a short course of insulin therapy, prolonged near-euglycemia is often possible because of restoration of pancreatic β-cell function and insulin sensitivity, with gradual cessation of insulin treatment and maintenance of glycemic goals with medical nutrition therapy and non-insulin agents (4). Such individuals often have clinical and metabolic features of T2D, including high rates of obesity, a strong family history of diabetes, a measurable pancreatic insulin reserve, the absence of autoimmune markers of β-cell destruction, and the ability to discontinue insulin therapy during follow-up (14,17).

This presentation of diabetes has been referred to in the literature as atypical diabetes or ketosis-prone T2D (14,17).

Epidemiologic studies conducted in the U.S. and Europe over the past decade have revealed a concerning rise in the rate of hyperglycemic emergencies in adults with both T1D and T2D (4–6, 13,18–21). This represents a marked departure from the previously observed improvements seen between 2000 and 2009 (6). During the first decade of the 21st century, reported incidence rates of DKA in adults with T1D in Europe, U.S., and Israel have varied between 0 and 56 events per 1,000 person-years, although one study conducted in China between 2010 and 2012 reported an outpatient rate of 263 per 1,000 person-years (22). No population-level data are available for HHS or mixed DKA/HHS frequencies.
is the most common precipitating factor for DKA, occurring in 14–58% of cases (3,24). Other acute conditions that may precipitate DKA include stroke, alcohol and substance use, pancreatitis, pulmonary embolism, myocardial infarction, and trauma (1,53–56).

The omission of insulin therapy, often in the setting of psychological and socioeconomic factors, is a major cause of DKA, particularly among adults with T1D living in socioeconomically deprived areas (1,24,48,54,57). A study assessing the clinical, socioeconomic, and psychological factors associated with DKA recurrence in urban patients from racial and ethnic minority backgrounds found discontinuation of insulin therapy to account for more than two-thirds of all DKA admissions (48).

Factors associated with a higher risk of hyperglycemic crisis in people with T1D include younger age, prior history of hyperglycemic and hypoglycemic crises, presence of kidney disease, neuropathy, depression, smoking, alcohol and substance abuse, high hemoglobin A1c (HbA1c), and social determinants of health (SDOH) (1,6,7,16,55,58). In people with T2D, risk factors include younger age, prior history of hyperglycemic or hypoglycemic crises, presence of comorbidities (both diabetes-related and unrelated), and elevated HbA1c and SDOH (7,16,42,48). Multiple studies have suggested that low income, area-level deprivation, housing insecurity, and lack of insurance or presence of underinsurance (e.g., having a high deductible health plan or Medicaid coverage in the U.S.) lead to increased risk of DKA and HHS (7,10,16,31,33,59,60), with approximately 40% of hyperglycemic crises occurring in lower-income and underserved populations (13,61). Food insecurity is also associated with triple the rate of DKA in youth and young adults with T2D (62). In addition, SDOH and mental health conditions are the strongest factors associated with recurrent DKA (23,25,31,42).

People with diabetes who have a history of DKA (compared with those without such a history) have been reported to have a significantly higher prevalence of mental health disorders such as depression, diabetes distress, substance abuse, psychoses, and bipolar disorder (63). Psychological comorbidities, including eating disorders, have been reported in recurrent episodes of DKA in young women (64,65). Depression and psychological comorbidities have a correlation
with decreased blood glucose monitoring and treatment engagement, which are associated with an increased risk of hospitalization for hyperglycemic crises (66). In addition, observational studies have reported that people with T1D and a history of DKA have an increased prevalence of depression and risk of hospitalization for a suicide attempt, with the highest risk of suicide attempt in the 12 months following the DKA episode (67,68). Importantly, the relationship between mental health conditions and hyperglycemic crises may be bidirectional, and all individuals experiencing hyperglycemic crises should be screened for mental health concerns. The Patient Health Questionnaire (PHQ-9) is the most used and validated screening test for depression in people with diabetes, with a high sensitivity and specificity (69). Importantly, symptoms associated with hyperglycemia may complicate screening because they may be mistaken for symptoms of depression (e.g., fatigue, hypersomnia, psychomotor slowing). In addition, screening for diabetes distress is indicated using the T1-Diabetes Distress Assessment System (T1-DDAS) to assess the degree of emotional burden related to diagnosis and management of diabetes, particularly T1D, that can influence management behaviors and clinical outcomes (70).

Recent studies have shown mixed results regarding the risk of DKA with insulin pump therapy. Some studies have shown improved glycemic goals and a reduced risk of both DKA and severe hypoglycemia in insulin pump users (71,72). However, other studies have shown higher rates of DKA with insulin pumps in T1D (73,74). In pump users presenting with DKA, the most common precipitating factors are management error and underlying infection; these are more common precipitating causes than device malfunction (74). As insulin pumps increasingly become integrated with continuous glucose monitoring (CGM) in automated insulin delivery systems, these systems may be associated with less DKA and higher rates of attaining glycemic management goals (75–77); however, larger studies and real-world data are still needed.

Several studies have reported DKA at the presentation of newly diagnosed T1D during or after a COVID-19 infection (9,78). The precise mechanisms for new-onset diabetes in people with COVID-19 are not known, but several complex interrelated factors are present at diagnosis in 69.7%, while patients presenting with DKA had glucose levels who are at particularly high risk

### Table 1—Precipitating causes of DKA in adults by region

<table>
<thead>
<tr>
<th>Region</th>
<th>New-onset diabetes</th>
<th>Infection</th>
<th>Insulin omission</th>
<th>Other</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>5.7</td>
<td>28.6</td>
<td>40</td>
<td>25.7</td>
<td>NR</td>
</tr>
<tr>
<td>Brazil</td>
<td>12.2</td>
<td>25</td>
<td>39</td>
<td>15</td>
<td>8.8</td>
</tr>
<tr>
<td>China</td>
<td>NR</td>
<td>39.2</td>
<td>24</td>
<td>10.9</td>
<td>25.9</td>
</tr>
<tr>
<td>Indonesia</td>
<td>3.3</td>
<td>58.3</td>
<td>13.3</td>
<td>17.1</td>
<td>8</td>
</tr>
<tr>
<td>South Korea</td>
<td>NR</td>
<td>25.3</td>
<td>32.7</td>
<td>11.2</td>
<td>30.8</td>
</tr>
<tr>
<td>Nigeria</td>
<td>NR</td>
<td>32.5</td>
<td>27.5</td>
<td>4.8</td>
<td>34.6</td>
</tr>
<tr>
<td>Spain</td>
<td>12.8</td>
<td>33.2</td>
<td>30.7</td>
<td>23.3</td>
<td>NR</td>
</tr>
<tr>
<td>Syria</td>
<td>NR</td>
<td>47.8</td>
<td>23.5</td>
<td>7.8</td>
<td>20.9</td>
</tr>
<tr>
<td>Taiwan</td>
<td>18.2</td>
<td>31.7</td>
<td>27.7</td>
<td>6.2</td>
<td>16.2</td>
</tr>
<tr>
<td>U.K.</td>
<td>6.1</td>
<td>44.6</td>
<td>19.7</td>
<td>10.9</td>
<td>18.7</td>
</tr>
<tr>
<td>U.S.</td>
<td>17.2–23.8</td>
<td>14.0–16.0</td>
<td>41.0–59.6</td>
<td>9.7–18.0</td>
<td>3.0–4.2</td>
</tr>
</tbody>
</table>

Data are %. Adapted from Dhathatiya et al. (3). NR, not reported.

### Table 2—Prevalence of DKA in adults by region

<table>
<thead>
<tr>
<th>Region</th>
<th>Precipitating factors</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>Volume depletion (%)</td>
<td>23.8%</td>
</tr>
<tr>
<td>Brazil</td>
<td>Diabetes (%)</td>
<td>14.0%</td>
</tr>
<tr>
<td>China</td>
<td>Hypersomnia (%)</td>
<td>7.7%</td>
</tr>
<tr>
<td>Indonesia</td>
<td>Fatigue (%)</td>
<td>41.0%</td>
</tr>
<tr>
<td>South Korea</td>
<td>Insomnia (%)</td>
<td>23.8%</td>
</tr>
<tr>
<td>Nigeria</td>
<td>Low-carbohydrate diets</td>
<td>77%</td>
</tr>
<tr>
<td>Spain</td>
<td>Prolonged fasting (%)</td>
<td>19.7%</td>
</tr>
<tr>
<td>Syria</td>
<td>Dehydration (%)</td>
<td>18.0%</td>
</tr>
<tr>
<td>Taiwan</td>
<td>Excessive alcohol intake (%)</td>
<td>18.0%</td>
</tr>
<tr>
<td>U.K.</td>
<td>Prolonged fasting (%)</td>
<td>18.0%</td>
</tr>
<tr>
<td>U.S.</td>
<td>Prolonged fasting (%)</td>
<td>18.0%</td>
</tr>
</tbody>
</table>

Data are %. Adapted from Dhathatiya et al. (3). NR, not reported.
for developing dehydration because of polyuria, age-related impairment of thirst mechanisms, and limited access to fluids (7,98). Infection is the major precipitating factor in 30–60% of patients with HHS, with urinary tract infections and pneumonia being the most common (99). Other common precipitating causes of HHS include acute cerebrovascular events, acute myocardial infarction, surgery, acute pancreatitis, and the use of drugs that affect carbohydrate metabolism by decreasing insulin release or activity. These include corticosteroids, sympathomimetic agents, and antipsychotic drugs (1,99).

Section 2. What Is the Pathogenesis of Hyperglycemic Crises?

The key difference between DKA and HHS is the degree of insulin insufficiency. The pathogenesis of these two diseases is presented in Fig. 1. DKA is characterized by severe insulin deficiency and a rise in concentrations of counterregulatory hormones (glucagon, cortisol, epinephrine, and growth hormones) (1,3,7). The resulting changes in the insulin/glucagon ratio lead to increased gluconeogenesis, accelerated glycogenolysis, and impaired glucose utilization by peripheral tissues. The combination of insulin deficiency and increased counterregulatory hormones results in the release of free fatty acids from adipose tissues (lipolysis), leading to unrestrained hepatic fatty acid oxidation and the production of excess ketone bodies with resulting ketonemia and metabolic acidosis (3).

In HHS, compared with DKA, there is less severe insulin deficiency and, therefore, sufficient insulin to prevent ketogenesis but not enough to prevent hyperglycemia, due to increased hepatic glucose production and decreased glucose utilization by peripheral tissues. Hyperglycemia leads to an osmotic diuresis, leading to volume depletion and hemoconcentration.

If fluid intake is not maintained, then this can lead to a hyperosmolar state, renal impairment, and, ultimately, a decline in cognitive function. (Fig. 1)

Hyperglycemia in people with hyperglycemic crises is associated with a severe inflammatory state characterized by an elevation of proinflammatory cytokines (tumor necrosis factor-α and interleukin-1, -6, and -8), C-reactive protein, reactive oxygen species, and lipid peroxidation biomarkers even in the absence of obvious infection or cardiovascular pathology (100). All these measurements return to near-normal values within 24 h following correction of hyperglycemia with insulin therapy and hydration.

Section 3. What Are the Diagnostic Criteria of DKA and HHS?

Diagnostic Criteria for DKA

The diagnosis of DKA should be based on the three criteria described in Fig. 2A. All
three components must be present to make this diagnosis. In this consensus report, we have defined hyperglycemia as a diagnostic criterion for DKA from >250 mg/dL (13.9 mmol/L) to either a glucose value of ≥200 mg/dL (11.1 mmol/L) or a prior history of diabetes irrespective of the presenting glucose value. Hyperglycemia and/or diabetes must be accompanied by two additional criteria—elevated ketones and metabolic acidosis—for the diagnosis of DKA to be established. Although hyperglycemia remains a key diagnostic criterion of DKA, a wide range of plasma glucose concentrations can be present on admission. Approximately 10% of patients with DKA present with euglycemic DKA, which is defined as plasma glucose levels <200 mg/dL (11.1 mmol/L) in the presence of ketosis and metabolic acidosis criteria of DKA described in Fig. 2 (91,101,102). Euglycemic DKA can be caused by a variety of factors, including exogenous insulin injection, reduced food intake, pregnancy, or impaired gluconeogenesis due to alcohol use, liver failure, and/or SGLT2 inhibitor therapy (103,104). In recent years, the use of SGLT2 inhibitors in those with T1D and T2D has accounted for the majority of cases of euglycemic DKA (105–107). In recognition of the wider range of glucose levels at presentation with DKA, the criteria for diagnosis of DKA have been changed to encompass a lower glucose value of >200 mg/dL (11.1 mmol/L) and a prior history of diabetes (irrespective of the glucose level) (2). The key diagnostic feature in DKA is the elevation of the circulating total ketone body concentration. Assessment of ketonemia can be performed semiquantitatively by the nitroprusside reaction in urine or serum, which measures acetoacetic acid (but not β-hydroxybutyrate, the main ketocacid produced in DKA), or quantitatively by direct measurement of β-hydroxybutyrate in blood from capillary point-of-care testing (POCT) or in the hospital laboratory (3). Both types of ketones have similar diagnostic sensitivity, but measuring β-hydroxybutyrate in blood is more specific for detecting DKA than measuring acetoacetate in urine (108).

Reliance on urine ketone testing can underestimate the severity of ketonemia early in the course of DKA because of a lag in the formation of acetoacetate, and conversely overestimate its severity later in the course of DKA when β-hydroxybutyrate is being cleared and converted into acetoacetate (3). In addition, several sulphydryl drugs (e.g., captopril) and medications such as valproate can give false-positive nitroprusside urine tests (109). Thus, for diagnosis and monitoring of the response to therapy, we recommend direct measurement of venous or capillary β-hydroxybutyrate, which is the main ketoacid in DKA (3,108). Blood concentrations of β-hydroxybutyrate ≥3.0 mmol/L correlate well with acid-base changes, with >90% sensitivity and specificity for the diagnosis of DKA (1,2,12). β-Hydroxybutyrate measurement can be performed on serum samples using laboratory analysis or capillary blood samples using handheld POCT meters with similar precision in quantifying β-hydroxybutyrate (3,108). Compared with a laboratory measurement, the convenience of testing and rapidity of results from POCT can reduce the time for assessment, duration of admission, and time to recovery from DKA (2,12,110). A systematic review of nine studies on the accuracy of capillary β-hydroxybutyrate measurement for identifying DKA, compared with multiple other analytical and clinical tests, reported high sensitivity, specificity, and positive and negative predictive values (111). However, there is concern about how accurate POCT instruments are compared with laboratory instruments for measuring β-hydroxybutyrate levels ≥5 mmol/L (108,112).

Most people with DKA present with a high anion gap metabolic acidosis. The anion gap is calculated by subtracting the major measured anions (chloride and bicarbonate) from the major measured cation (sodium). An anion gap >20 mmol/L indicates the presence of a high anion gap metabolic acidosis consistent with DKA. However, mixed acid-base disorders are present in about one-third of those presenting with DKA because of hyperglycemia-induced osmotic diuresis and natriuresis, nausea and vomiting leading to volume contraction and metabolic alkalosis, and a compensatory respiratory alkalosis caused by hyperventilation due to rapid and/or deep breathing (Kussmaul breathing) (113,114). In addition, hyperchloremic normal anion gap acidosis is commonly seen following successful treatment of DKA and may delay transition back to subcutaneous insulin if mistaken for persistent DKA (7,115). Although the anion gap is not recommended as a first-line diagnostic or resolution criterion for these reasons, it may still have some utility in resource settings where ketone measurement is unavailable.

---

**Figure 2**—The diagnosis criteria of DKA (A) and HHS (B).

### A. DKA Diagnostic Criteria

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes/hyperglycemia</td>
<td>Glucose ≥200 mg/dL (11.1 mmol/L) OR prior history of diabetes</td>
</tr>
<tr>
<td>Ketosis</td>
<td>β-Hydroxybutyrate concentration ≥3.0 mmol/L OR urine ketone strip 2+ or greater</td>
</tr>
<tr>
<td>Metabolic Acidosis</td>
<td>pH &lt;7.3 and/or bicarbonate concentration &lt;18 mmol/L</td>
</tr>
</tbody>
</table>

### B. HHS Diagnostic Criteria

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperglycemia</td>
<td>Plasma glucose ≥600 mg/dL (33.3 mmol/L)</td>
</tr>
<tr>
<td>Hyperosmolarity</td>
<td>Calculated effective serum osmolality &gt;300 mOsm/kg (calculated as [2xNa⁺ (mmol/L) + glucose (mmol/L)] + [2xNa⁺ (mmol/L) + glucose (mmol/L) + urea (mmol/L)])</td>
</tr>
<tr>
<td>Absence of significant ketonemia</td>
<td>β-Hydroxybutyrate concentration &lt;3.0 mmol/L OR urine ketone strip less than 2+</td>
</tr>
<tr>
<td>Absence of acidosis</td>
<td>pH ≥7.3 and bicarbonate concentration ≥15 mmol/L</td>
</tr>
</tbody>
</table>

---

(Tables and figure citations are for illustrative purposes only and are not part of the original text.)
The severity of DKA is classified as mild, moderate, or severe based on the magnitude of metabolic acidosis (blood pH, serum bicarbonate, and ketone levels) and the presence of altered mental status, as presented in Table 2 (12). This categorization may be clinically useful for guiding the location where an individual is assigned to receive care (e.g., emergency department, intensive care unit [ICU], or step-down unit) and for identifying patients with mild DKA who are candidates for subcutaneous insulin dosing rather than intravenous insulin infusion (116). However, not all variables need to be fulfilled to be defined as either mild, moderate, or severe, and the admission site and level of care are ultimately a clinical decision.

### Diagnostic Criteria for HHS
HHS is a state of significant hyperglycemia and hyperosmolality in the absence of severe ketonemia and metabolic acidosis. The diagnosis of HHS should be based on the four criteria presented in Fig. 2B. All four components must be present to make the diagnosis (12,117).

### Clinical overlap between DKA and HHS
DKA and HHS have been reported in more than one-third of people with hyperglycemic crises (50). Although most people with HHS have an admission pH ≥7.30 and a bicarbonate level ≥18 mmol/L, mild ketonemia may be present.

### Clinical Presentation of DKA and HHS
Figure 3 illustrates common clinical features in individuals admitted with DKA and HHS. In DKA, the time between initial symptoms and acute presentation may be hours to a few days, whereas with HHS, it may take days or weeks to develop. Both conditions may present with polyuria, polydipsia, weight loss, vomiting, dehydration, and change in cognitive state. The respiratory compensation for metabolic acidosis found in DKA is manifest by Kussmaul breathing, which consists of deep breaths with a fruity odor smell because of the presence of acetone (a breakdown product of the ketone acetoacetic acid) in the breath. Changes in cognitive state are usually present in patients with severe DKA and HHS. Nausea, vomiting, and abdominal pain are common in DKA (>50%) but are uncommon in HHS (118). Caution is needed with patients who present with abdominal pain because the symptoms could be either a result of the DKA or an indication of a precipitating cause of DKA, particularly in the absence of severe metabolic acidosis. Further clinical evaluation is necessary if this complaint is not resolved with the resolution of dehydration and metabolic acidosis.

If DKA or HHS is suspected, initial samples should be taken for glucose, serum electrolytes, venous blood gases, complete blood count, and blood or urine ketone levels. Volume status can be assessed with vital sign parameters. Tachycardia and hypotension correlate with severe hypovolemia. However, some patients can maintain hemodynamic stability and intravascular volume because of the hypertonicity associated with hyperglycemia and the subsequent movement of intracellular water into the extracellular space. Patients should be examined for signs of infection, ischemia, and other potential precipitants of a hyperglycemic crisis. In addition, an electrocardiogram...
should be performed to assess for evidence of biochemically induced repolarization abnormalities, such as peaked T waves from hyperkalemia and ischemia.

It is important to consider the differential diagnosis of elevated ketones, including starvation ketosis, alcoholic ketoacidosis, and ketosis of pregnancy and hyperemesis (3). The diagnosis of starvation ketosis is suggested by a history of dietary intake of <2,090 kcal/day (500 kcal/day), which is associated with low insulin concentrations, leading to ketone production. People with chronic ethanol use with a recent binge culminating in vomiting and acute starvation may develop ketoacidosis with or without hyperglycemia (119,120). The vomiting of hyperemesis gravidarum leads to excess counterregulatory hormone concentrations, also predisposing to ketone formation.

Section 4. What Is the Recommended Treatment of DKA and HHS?

DKA and HHS have a similar underlying pathogenesis consisting of insulin deficiency, increased counterregulatory hormones, and loss of fluid and electrolytes. The management of DKA and HHS includes the administration of intravenous fluids, insulin, and electrolytes as well as identification and treatment of the precipitating cause. Capillary blood glucose testing should be performed during treatment every 1–2 h using a hospital-calibrated glucose meter, and blood should be drawn every 4 h for determination of electrolytes, phosphate, creatinine, β-hydroxybutyrate, and venous pH until resolution of DKA. In patients with HHS, in addition to measuring glucose, creatinine, and electrolytes, serum osmolality should be measured every 4 h. Treatment pathways for DKA and HHS emphasizing intravenous fluids, short-acting insulin, and potassium are illustrated in Fig. 4.

Most people with uncomplicated mild or moderate DKA can be treated in the emergency department or a step-down unit if close nursing supervision and monitoring are available (121). In such patients, several comparisons of treating DKA in the ICU versus step-down and general nursing units have not demonstrated clear differences in mortality rate, length of hospital stay, or time to resolution of ketoacidosis. ICU admission in people with mild DKA has also been associated with more laboratory testing and higher hospitalization costs (122,123). In contrast, individuals with severe DKA or HHS, or those with critical illness as the precipitating cause (e.g., myocardial infarction, gastrointestinal bleeding, sepsis) or with altered mental status (1,3,12,124) should be treated in the ICU, as outlined in Table 2.

Fluid Therapy

Initial intravenous fluid resuscitation restores the effective circulating intravascular volume, increases tissue/orga perfusion (which decreases lactate formation), improves renal perfusion (which promotes renal excretion of glucose and ketone bodies), corrects electrolyte deficits, and decreases plasma osmolality. In addition, correction of a fluid deficit improves insulin sensitivity by reducing counterregulatory hormone concentrations (7,12). Mean plasma glucose...
concentrations have been reported to drop by approximately 50–70 mg/dL/h (2.8–3.9 mmol/L/h) solely in response to intravenous fluid administration in the absence of insulin (2). This rate of decrease may be even more pronounced in HHS.

The fluid choice for initial resuscitation should be determined by local availability, cost, and resources. Most clinical guidelines recommend the administration of isotonic saline (0.9% sodium chloride solution) as the initial resuscitation fluid because of its widespread availability, lower cost, and efficacy in restoring circulating volume in clinical studies (2,12). While effective, its use in large volumes may be associated with hyperchloremic normal anion gap metabolic acidosis and prolonged length of ICU and hospital stay (125). Recent prospective and observational studies and meta-analyses have reported that the administration of balanced crystalloid solutions (e.g., Ringer’s lactate or plasmalyte-148), compared with the administration of the isotonic saline solution, results in faster DKA resolution (125–129), shorter hospital length of stay, and less frequent development of hyperchloremic metabolic acidosis.

In adults with DKA or HHS without renal or cardiac compromise, we recommend starting the administration of isotonic saline or balanced crystalloid solutions at an initial rate of 500–1,000 mL/h during the first 2–4 h. After restoration of intravascular volume, the subsequent choice for fluid replacement depends on the state of hydration assessed by blood pressure, heart rate, fluid input-output balance, and sodium concentration. Fluid replacement should correct estimated deficits within the first 24–48 h. However, caution should be used when rapidly replacing fluids in those at high risk of fluid overload, including older adults, pregnant individuals, and people with heart or kidney disease or other serious comorbidities.

In patients with DKA, plasma glucose concentrations usually decrease to <250 mg/dL (13.9 mmol/L) within 4–8 h, which is before ketoacidosis resolves (130). Thus, once the plasma glucose concentration is <250 mg/dL (13.9 mmol/L), replacement fluids should be modified to contain 5–10% dextrose in addition to the 0.9% sodium chloride to prevent hypoglycemia and allow continued insulin administration until the ketonemia is corrected (7,12).

In patients with HHS, the usual time to resolve hyperglycemia is between 8 and 10 h and the decline should not exceed 90–120 mg/dL/h (5–6.7 mmol/L/h) to prevent cerebral edema. Similarly, the rate of decline of serum sodium should not exceed 10 mmol/L in 24 h and the rate of fall in osmolality should be no greater than 3.0–8.0 mOsm/kg/h to minimize the risk of neurological complications (117). Initial fluid replacement will lower the glucose concentration and osmolality, causing a shift of water into the intracellular space, which may result in a rise in serum sodium (a reduction of 100 mg/dL [5.6 mmol/L] of glucose will result in a 1.6 mmol/L rise in sodium concentration). The initial rise in serum sodium is not an indication to give hypotonic fluids, and the administration of 0.45% sodium chloride is indicated only if osmolality is not declining despite adequate positive fluid balance and appropriate insulin administration. Some have recommended that insulin be withheld until glucose has stopped dropping, with initial fluid administration alone to prevent a rapid fall in osmolality (117).

Older adults with DKA or HHS, as well as individuals with heart failure or end-stage kidney disease on dialysis, should be treated cautiously with smaller boluses of isotonic or crystalloid solutions (e.g., 250 mL boluses) and should undergo frequent assessment of hemodynamic status (131). In such patients, the use of a standard fluid replacement protocol may be associated with treatment-related complications, including volume overload, need for mechanical ventilation, and longer length of stay (131).

Insulin

Insulin therapy is the cornerstone of DKA management and should be started as soon as possible after diagnosis. Short-acting insulin administered intravenously by continuous infusion is the preferred choice. Depending on the severity of the condition and the available facilities, this should be done using a fixed-rate intravenous insulin infusion started at 0.1 units/kg/h (1–3,12,132) or by a nurse-driven insulin infusion protocol with a variable rate for DKA (133). In adults, treatment protocols recommend the initial administration of an insulin bolus (0.1 units/kg) (intravenously or intramuscularly) if a delay in obtaining venous access is anticipated to be followed by fixed-rate intravenous insulin infusion (12). Once the blood glucose falls below 250 mg/dL (13.9 mmol/L), 5–10% dextrose should be added to the 0.9% saline infusion and the insulin infusion rate should be reduced to 0.05 units/kg/h. Thereafter, intravenous insulin infusion should be adjusted to maintain glucose levels at approximately 200 mg/dL (11.1 mmol/L) and continued until the ketoacidosis is resolved (1–3).

In people on basal or basal-bolus insulin therapy before admission, this regimen can be continued at the usual dose and adjusted as needed. In those newly diagnosed, multidose insulin regimens with basal and prandial rapid-acting insulin analogs should be started after the resolution of DKA (1,12). Long-acting basal insulin should be initiated subcutaneously at 0.15–0.3 units/kg. This medication may be administered once daily or divided equally and administered twice daily. Rapid-acting insulin is added as needed, depending on nutritional intake and glucose levels.

The administration of basal insulin while on fixed-rate intravenous insulin infusion is advocated by many clinicians but avoided by others because of the risk of hypoglycemia (134) or hypokalemia (135). Several studies have reported that the coadministration of a low dose (0.15–0.3 units/kg) of basal insulin during insulin infusion reduces time to DKA resolution, duration of insulin infusion (136,137), and length of hospital stay (136) and prevents rebound hyperglycemia, all without increased risk of hypoglycemia (136,138,139).

Patients with uncomplicated mild or moderate DKA may be treated with subcutaneous rapid-acting insulin analogs (130,138,140). Several randomized studies and a meta-analysis have reported that the administration of subcutaneous rapid-acting insulin analogs every 1–2 h is an effective alternative to intravenous infusion of short-acting insulin for people with mild or moderate DKA (138,141,142). This treatment can be delivered in emergency departments and step-down units without the need for ICU care. A 2016 Cochrane review suggested that there were neither advantages nor disadvantages to using subcutaneous insulin over intravenous insulin when treating mild or moderate DKA (138). Intramuscular rapid-acting insulin is also effective for treating DKA, but this route is more painful than subcutaneous...
injection and might increase the risk of bleeding for patients receiving anticoagulation therapy (1,143). The use of rapid-acting subcutaneous insulin analogs is not recommended for the treatment of severe and complicated DKA or with HHS.

Few studies have assessed the optimal insulin regimen in HHS. If the individual is already being treated with basal insulin, it should be continued at the usual dose and adjusted as needed. If HHS is present with no ketosis or with mild or moderate ketonemia (blood β-hydroxybutyrate ≥1.0 to <3.0 mmol/L or urine ketones <2+), and without acidosis (pH ≥7.3 and bicarbonate ≥18 mmol/L), then a fixed-rate intravenous insulin infusion should be started at 0.05 units/kg/h. If significant ketonemia is present (i.e., β-hydroxybutyrate ≥3.0 mmol/L, ketonuria ≥2+, pH <7.30, or bicarbonate <18 mmol/L), which represents mixed DKA/HHS, then a fixed-rate intravenous insulin infusion should be started at 0.1 units/kg/h (117).

**Transition to Maintenance Insulin Therapy**

In the hospital, patients with DKA will eventually transition from intravenous to subcutaneous insulin, as illustrated in Fig. 5. To prevent the recurrence of hyperglycemia or ketoacidosis during the transition period to subcutaneous insulin, it is important to allow an overlap of 1–2 h between the administration of subcutaneous insulin and the discontinuation of intravenous insulin. Patients with known diabetes may be given insulin at the dosage they were receiving before the admission. If there is concern for inadequate baseline insulin therapy (i.e., high HbA1c) or any potentially precipitating drug as a contributing factor to the DKA or HHS event, then the treatment regimen should be changed at discharge and not deferred to outpatient follow-up (1,3,12).

To transition from intravenous to subcutaneous insulin therapy, an estimation of the total daily insulin requirement is needed. This estimated total daily dose (TDD) of insulin may be calculated using several methods based on weight, preadmmission insulin regimen, or intravenous insulin requirements. However, each of these methods has limitations that must be considered when assessing overall insulin needs. First, a weight-based formula may be considered for TDD calculation using 0.5–0.6 units/kg/day in insulin-naive patients, with the understanding that body composition and/or insulin resistance may impact this estimate (7,12). Similarly, for people with risk factors for hypoglycemia, including kidney failure or frailty, a calculation using approximately 0.3 units/kg/day may be more appropriate. Second, consideration of the predmission outpatient insulin regimen and HbA1c levels may help guide transition dosing needs. However, it is necessary to understand how medication-taking behaviors and dietary factors may have influenced outpatient insulin dosing recommendations. Finally, TDD may be calculated by considering the hourly intravenous insulin infusion rate requirements, but with caution given the potential variation in insulin needs based on factors such as glucotoxicity, duration of treatment with intravenous insulin, concurrent dextrose infusion, medications associated with hyperglycemia, and nutritional intake (144). Once a TDD estimate has been determined, a multidose insulin regimen should be started, with basal insulin initiated at least 1–2 h before cessation of intravenous insulin infusion. Although first-generation basal analogs and NPH insulin are frequently administered once a day, greater flexibility and better coverage of basal insulin needs may be obtained if they are administered twice daily. The use of a basal-bolus insulin regimen with basal and rapid-acting insulin analogs has been proposed as a more physiologic regimen and has been reported to reduce the rate of hypoglycemia after transition from intravenous to subcutaneous insulin after resolution of DKA compared with human (i.e., short-acting and NPH) insulins (130). Human insulin regimens may also be used, but proper dosing should ensure 24-h insulin coverage. There are no current studies on transitioning to ultra-long-acting insulin (e.g., degludec, glargine U300).

**Potassium**

Despite experiencing a total-body potassium depletion of 3–6 mmol/kg due to long-standing osmotic diuresis, emesis, and hyperaldosteronism (7), most patients with DKA present with normal or high serum potassium levels (10,145). This is because metabolic acidosis and insulin deficiency cause the movement of potassium from the intracellular to the extracellular compartment (146). Insulin therapy, correction of acidosis, volume expansion, and increased kaliuresis decrease serum potassium. Within 48 h of admission, potassium levels typically decline by 1–2 mmol/L during treatment of DKA, HHS, and mixed DKA/HHS (24). To prevent hypokalemia, potassium replacement should be started after serum levels fall below 5.0 mmol/L to maintain a potassium level of 4–5 mmol/L (2,12).

For most patients with DKA, 0.8–3.0 mmol/kg of potassium per liter of intravenous fluid is sufficient to maintain a serum potassium concentration within the target range. Low-normal or low potassium levels (<3.5 mmol/L) are present on admission in 5–10% of patients with DKA (147); in such cases, potassium replacement should begin at a rate of 10 mmol/h, and insulin therapy should be delayed until the potassium level increases to >3.5 mmol/L to avoid life-threatening arrhythmias and respiratory muscle weakness (147). Severe hypokalemia =2.5 mmol/L during treatment of DKA and HHS has been reported to be associated with a threefold increase in mortality (10). To avoid hypokalemia, we recommend measuring serum potassium 2 h after starting insulin administration and every 4 h thereafter until the resolution of DKA. Use of too low or too high doses of potassium compared with the recommended potassium replacement protocols in the management of DKA has been associated with longer hospital stays (148).

**Bicarbonate**

Routine bicarbonate administration is not recommended. Intravenous fluid resuscitation and insulin administration are usually sufficient to resolve the metabolic acidosis of DKA (24,149). Several observational and randomized studies have reported that bicarbonate administration in DKA offers no advantage in improving cardiac or neurologic outcomes or in the rate of recovery of hyperglycemia and ketoacidosis (3,12). In addition, potential detrimental effects of bicarbonate therapy have been reported, such as an increased risk of hypokalemia, decreased tissue oxygen uptake, cerebral edema, and development of paradoxical central nervous system acidosis (3). However, because severe metabolic acidosis may lead to adverse vascular effects, bicarbonate administration should be considered if the acidosis is severe (i.e., pH <7.0) (146,150). If indicated, then 100 mmol of sodium bicarbonate (8.4% solution) in 400 mL
of sterile water (an isotonic solution) can be given every 2 h to achieve a pH > 7.0 (12).

**Phosphate**
In DKA, there is a shift of phosphate from intracellular to extracellular fluid, with an excess urinary phosphate loss leading to hypophosphatemia (151). Whole-body losses can be up to 1.0 mmol/kg; however, unless there is evidence of muscle weakness, such as respiratory or cardiac compromise with the phosphate < 1.0 mmol/L, routine administration of phosphate is not indicated. Several prospective randomized studies have failed to show any beneficial effect of phosphate replacement on the clinical outcome of DKA (3,152), and excessively rapid phosphate replacement may precipitate hypocalemia (152). When necessary, 20–30 mmol of potassium phosphate can be added to replacement fluids. There is scarce data on phosphate deficiency or the effects of phosphate replacement in HHS, so we recommend a similar approach to phosphorus replacement.

**Criteria for Resolution of DKA and HHS**
Resolution of DKA is defined as achieving plasma ketone < 0.6 mmol/L and venous pH ≥ 7.3 or bicarbonate ≥ 18 mmol/L (2). Ideally, the blood glucose concentration should also be < 200 mg/dL (11.1 mmol/L). The anion gap should not be used as a criterion, as it may be misleading because of the presence of hyperchloremic metabolic acidoses caused by large volumes of 0.9% sodium chloride solution. Because β-hydroxybutyrate is converted into acetoacetate as the acidosis improves, urinary ketone measurement should be avoided as a criterion of DKA resolution.

While there is no consensus on the definition for resolution of HHS, we consider HHS to be resolved when the measured or calculated serum osmolality falls to < 300 mOsm/kg, hyperglycemia has been corrected, urine output is > 0.5 mL/kg/h, and the blood glucose is < 250 mg/dL (13.9 mmol/L) (12,117).

**Section 5. What Are Complications During Treatment?**
Table 3 describes current evidence, risks, and mitigation strategies of the most important complications of treating acute hyperglycemic crises in adults, including hypoglycemia, hypokalemia, normal anion gap metabolic acidosis, thrombosis, cerebral edema, osmotic demyelination syndrome, and acute kidney injury.

**Section 6. What Are the Recommended Management Strategies for Special Populations?**
Table 4 highlights some important considerations regarding DKA and HHS in special populations. These conditions or scenarios include frail older adults, individuals receiving SGLT2 inhibitor therapy,
### Table 3—Complications during treatment of DKA and HHS

<table>
<thead>
<tr>
<th>Complication</th>
<th>Evidence</th>
<th>Risk</th>
<th>Mitigation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypoglycemia (10,24)</strong></td>
<td>Hypoglycemia is a common complication encountered in the treatment of DKA.</td>
<td>Hypoglycemia (&lt;40 mg/dL [2.2 mmol/L]) during treatment was associated with a 4.8-fold increase in mortality (adjusted OR 4; 95% CI 1.4–16.8).</td>
<td>Frequent blood glucose monitoring (every 1–2 h) is mandatory to recognize hypoglycemia.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>When glucose levels are reduced to &lt;250 mg/dL (13.9 mmol/L), it is advised to reduce the insulin infusion rate to 0.05 units/kg/h and replacement fluids should be modified to contain 5–10% dextrose to prevent hypoglycemia.</td>
</tr>
<tr>
<td><strong>Hypokalemia (24)</strong></td>
<td>Hypokalemia is a common complication owing to intracellular shift of potassium following insulin treatment.</td>
<td>Severe hypokalemia ≤2.5 mmol/L was associated with increased inpatient mortality (adjusted OR 4.9; 95% CI 1.3–18.8).</td>
<td>Potassium should be carefully monitored every 4 h during treatment.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Potassium replacement should be added to fluid resuscitation.</td>
</tr>
<tr>
<td><strong>Normal anion gap metabolic acidosis (173,174)</strong></td>
<td>Hyperchloremic non-anion gap acidosis may be seen during the recovery phase of DKA, but the risk is unknown. It is likely to be caused by loss of keto-anions, which are metabolized to bicarbonate, and excess fluid infusion of chloride-containing fluids during treatment.</td>
<td>Observed during the recovery phase of DKA, it is self-limiting with few clinical consequences.</td>
<td>There is some evidence that hyperchloremic acidosis occurs less frequently with balanced electrolyte solutions and when slower saline infusion is administered.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Thrombosis (43,175,176)</strong></td>
<td>Both DKA and HHS, but especially HHS, are thought to be prothrombotic states.</td>
<td>Although case series highlight the risk of venous and arterial thromboembolism in HHS, a nationwide Taiwanese study examining the risk of venous thromboembolism in people with HHS versus those hospitalized without HHS found similar rates.</td>
<td>Currently, unless thrombosis is suspected, prophylactic dose low-molecular-weight heparin should be used to mitigate the risk of thrombosis.</td>
</tr>
<tr>
<td></td>
<td>There is evidence that clot microstructure may be altered in people with acidosis and dehydration, but this is reversible.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cerebral edema (3,177)</strong></td>
<td>Cerebral edema is rare in adults. The underlying cause is not fully understood but may reflect osmotic changes, hypoperfusion, and/or inflammatory responses.</td>
<td>Cerebral edema is a serious complication with a reported mortality of ~30% compared with those without edema.</td>
<td>Recognizing potential risk factors and being alerted to changes in mental status is advised, with a low threshold for brain imaging.</td>
</tr>
<tr>
<td></td>
<td>In adult patients with HHS and DKA, rapid shifts in osmolarity may also be associated with cerebral edema thought to occur in &lt;0.1% of events.</td>
<td>Cerebral edema may be subclinical and visible only on imaging studies.</td>
<td>Mannitol infusion and mechanical ventilation are suggested for treatment of cerebral edema.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In adults with HHS, a slow rate for correction of hyperosmolality is indicated.</td>
</tr>
<tr>
<td><strong>Osmotic demyelination syndrome (117,178)</strong></td>
<td>Previously known as central pontine myelinolysis, osmotic demyelination syndrome can occur with rapid correction of hyponatremia. The incidence is unclear.</td>
<td>The risk is specifically associated with rapid correction of hyponatremia.</td>
<td>In patients with HHS, the fall in serum osmolality should be corrected with 0.9% saline solution.</td>
</tr>
<tr>
<td></td>
<td>May complicate treatment of adults with HHS where hyperosmolar patients may be relatively hyponatremic.</td>
<td></td>
<td>The fall in serum osmolality should be between 3.0 and 8.0 mOsm/kg/h.</td>
</tr>
</tbody>
</table>

*Continued on p. 13*
end-stage kidney disease requiring dialysis, pregnancy, and COVID-19 infection.

### Section 7. How Can DKA and HHS Be Prevented?
Key issues at the time of hospital discharge include transitions of care, therapeutic inertia, the risk of hypoglycemia, and prevention of recurrent severe hyperglycemic events. In U.S. nationwide studies, up to 22% of people admitted with DKA had at least one readmission within 30 days or the same calendar year (25,153). Among those readmitted within 30 days, 40.8% represented recurrent DKA episodes, with approximately 50% being readmitted within 2 weeks (25). Among those readmitted within the same calendar year, 86% and 14% had 1 and 2 readmissions, respectively (153). Assessment of precipitating and contributing causes of DKA admission and close follow-up within 2–4 weeks after discharge may reduce recurrent DKA (154). For example, the Novel Interventions in Children’s Healthcare program supports families with children who have had multiple admissions for recurrent DKA (154,155). Similarly, close observation, early detection of symptoms, and timely medical care help prevent HHS in older adults (154). Presence of mental health disorders and SDOH need to be assessed on admission and before discharge. Extensive evidence indicates that mental health conditions—particularly eating disorders, depression, or schizophrenia—are independent risk factors for poor glycemic control and DKA (156). Thus, regular screening of people with diabetes for psychological and behavioral disorders should be implemented in clinical practice.

Socioeconomic disadvantage is a major risk factor for DKA and HHS. Several indicators of socioeconomic disadvantage have been associated with an increased risk of hyperglycemic crises. These include low income, homelessness, lack of health insurance or underinsurance, food insecurity, and low educational attainment (59).

In a recent study, people from an area with the lowest income quartile had a 46% increase in the odds of four or more DKA readmissions in a given calendar year, while a patient with Medicare insurance had over a threefold increased odds of this outcome compared with those with private insurance (59). In the U.S., policy solutions such as increasing access to health insurance, affordable insulin, medical care, nutritious food, and housing would be expected to reduce the incidence of DKA (157).

Before discharge, all individuals admitted with DKA or HHS should be offered appropriate education focused on both the current event and overall diabetes management. Patient education—especially structured education that includes problem-solving—is effective at reducing DKA admissions (158). Participation in a structured diabetes education program leads to a substantial risk reduction for DKA and HHS (156). In patients with recurrent DKA, up to 75% of the admissions have been attributed to insufficient use of insulin therapy (i.e., missed insulin doses) as the immediate contributing factor (48). Omission or insufficient use of insulin therapy is a major cause of DKA admissions and readmissions (159). Thus, education on insulin administration and “sick day advice” must be provided or reinforced. Upon discharge, patients should receive an adequate supply of insulin and diabetes-durable medical equipment (i.e., glucose monitoring and insulin administration devices) as well as contact information for health care professionals who can assist in managing future episodes of high blood glucose and ketone concentrations. For individuals with poor access to insulin, the social service department should be consulted to address these barriers to optimal self-management.

Education should include reviewing injection techniques (including sites), glucose monitoring, and urine or blood ketone testing (160). Each patient and their family need to review the appropriate glucose and ketone monitoring and when to call for assistance. Home measurement of capillary blood and serum ketones helps to identify impending DKA (156). Unfortunately, the rate of appropriate ketone monitoring, especially in adults, is low among people with diabetes (158,161).

The ADA-EASD consensus report on T1D recommends CGM as the monitoring method of choice for most people with T1D (162). CGM is superior to capillary blood glucose monitoring for improving glycemic patterns among insulin-treated patients with T1D and T2D, especially those with out-of-range glucose levels. Results from a nationwide study in France reported that access to a CGM system was associated with a subsequent decrease in the rate of DKA hospitalizations by 53% and by 47% in T1D and T2D, respectively (163). These results were observed both in patients treated with multidose insulin and in those treated with continuous insulin infusion (pump) therapy (164) Although CGM has not been approved for use in hospitalized patients with diabetes or with DKA, real-time or intermittently scanned CGM should be offered to people admitted with DKA after hospital discharge (165).

In individuals with multiple episodes of DKA, intensified and multidisciplinary approaches such as psychological interventions, peer support, individual coaching, and behavioral family systems therapy have been reported to reduce DKA risk (156). In addition, the use of telemedicine and digital communication methods, as well as the provision of a 24-h emergency call service that offers medical advice for symptoms of DKA or when blood glucose or ketone concentrations are high, may reduce the risk of DKA admissions (156).

### Table 3—Continued

<table>
<thead>
<tr>
<th>Complication</th>
<th>Evidence</th>
<th>Risk</th>
<th>Mitigation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute kidney injury (179,180)</td>
<td>• Using RIFLE (risk, injury, failure, loss) criteria, 50% of adult patients admitted with DKA and HHS have acute kidney injury.</td>
<td>• Acute kidney injury is more common in older adults, those with higher osmolality, and those with higher admission glucose levels.</td>
<td>• Acute kidney injury usually resolves with rehydration. Monitoring renal function daily is recommended.</td>
</tr>
</tbody>
</table>

### Areas for Future Research?
To date, clinical recommendations for the management of DKA and HHS are largely based on consensus and opinion rather...
than rigorous outcomes research. Thus, large randomized controlled trials or robust observational studies conducted in generalizable settings and populations are needed to determine the best management options, including optimizing the electrolyte content of intravenous fluids (0.9% sodium chloride vs. crystalloid solutions) as well as the optimal rates and techniques for insulin administration (2). Small case series and retrospective studies suggest worse outcomes in patients with HHS compared with those with isolated DKA and that mixed DKA and HHS have worse outcomes compared with isolated DKA or HHS (2,10). However, no prospective studies have determined the best treatment for HHS and the combination of DKA and HHS. Dhathiriya et al. reported that despite potassium replacement following protocol in the U.K., 67% of

| Table 4—Features of DKA and HHS occurring in special populations |
|----------------------|----------------------|----------------------|----------------------|----------------------|
| Special population   | Clinical characteristics and presentation | Diagnostic considerations | Specific management considerations | Future care considerations |
| Frail or older adults (181) | • High rate of preexisting comorbidities. • High risk for hospital mortality, prolonged hospitalization, and DKA recurrences. | • Isolated HHS and mixed DKA/HHS occur more frequently than DKA. • Evaluate for specific precipitating factors and concurrent diagnoses (cardiovascular events, infection, medications). | • Fluid resuscitation and rate of fluid replacement need to account for comorbidities and acute precipitating events. • Address polypharmacy. | • Assessment of cognitive and functional status, including capacity for self-management. • Continued management of comorbidities and risk factors for DKA/HHS recurrence. |
| SGLT2 inhibitor (91,93,109,182) | • May be spontaneous or preceded by insulin dose reduction or insulin omission, prolonged fasting, or acute illness. • May be prevented using specific “sick day rules.” | • May present with near-normal glucose concentrations or euglycemic DKA (glucose <200 mg/dL [11.1 mmol/L]). | • Acute management as for “general” DKA. In euglycemic DKA, 5–10% dextrose should be added to intravenous fluid or started at the same time as the 0.9% sodium chloride. • SGLT2 inhibitors should be stopped on admission. | • SGLT2 inhibitor therapy is not recommended for patients with T1D. • In patients with T2D, because of the lack of safety data, initiation or continuation of SGLT2 inhibitor therapy after DKA resolution is not routinely recommended. |
| End-stage kidney disease (2,183) | • About 4% of patients with diabetes and end-stage kidney disease experienced DKA/HHS. • May present with fluid overload. High preexisting comorbidity burden with increased risk of mortality. | • Patients with end-stage kidney disease usually present with greater hyperglycemia, more frequent hyponatremia, higher osmolality, hyperkalemia, and lower ketone concentrations of β-hydroxybutyrate compared with patients without end-stage kidney disease. | • Careful fluid administration and potassium replacement are needed. • Greater risk of cardiac co-complications. | • Holistic multidisciplinary care and aggressive multiple risk factor intervention is necessary. • Closer glucose and ketone monitoring is necessary. |
| Pregnancy (160,184) | • Up to 2% of pregnancies with gestational diabetes develop DKA. • Most cases occur with preexisting T1D. • The incidence of DKA in gestational diabetes is low (<0.1%). | • Euglycemic DKA (glucose <200 mg/dL [11.1 mmol/L]) may occur. • Mixed acid-base disturbances may occur with hyperemesis, making the diagnosis challenging. | • The significant feto-maternal risk requires immediate expert senior medical and obstetric intervention. • Ideally patients should be cared for in delivery suites or high-dependency units. | • Management guidelines in the emergency department or obstetric unit should include sections on the management of DKA in pregnancy as well as sick day rules. |
| COVID-19 (79,185) | • Higher frequency of DKA during the COVID-19 pandemic. • At-risk groups are adults with preexisting T2D. • High risk for complications, need for ICU care, longer hospital stays, and mortality. | • Usual diagnostic criteria. • Higher frequency of mixed DKA/HHS especially in older adults. | • Treatment with high-dose steroids requires higher-dose insulin to treat refractory ketonemia. • In newly diagnosed individuals presenting with diabetes in DKA, diabetes phenotyping may be helpful. | • Discharge on insulin treatment with careful follow-up. |
patients had a potassium level < 4 mmol/L within 24 h of presentation (24). Similar findings were reported in Canada (166) and the U.S. (10), where approximately 50% of patients developed hypokalemia (< 3.5 mmol/L) despite 91% of them receiving potassium replacement. Additional studies are needed to determine the ideal potassium replacement regimen in this clinical setting.

A high ketone concentration is the hallmark of DKA, with a consensus among clinical guidelines that a concentration ≥ 3 mmol/L correlates with acid-base parameters and severity of acidosis with clinical guidelines that a concentration increased risk of DKA. Insulin supply remains a challenge in low-income countries despite insulin being included on the World Health Organization’s list of essential medications. Additionally, further research is needed to understand better and ultimately eliminate the disparities in DKA and HHS rates experienced by racial and ethnic minority communities (16,172). In the U.S., these disparities exist independent of other confounding risk factors for hyperglycemic crises. Data on racial and ethnic disparities in DKA and HHS rates outside the U.S. are scarce and need to be examined. Ultimately, these disparities may call for comprehensive structural solutions, including at the clinician, health system, payer, public health, and public policy levels. Optimal management of DKA and HHS will require greater knowledge of the pathophysiological, clinical, and social roots of these serious complications of diabetes.

Acknowledgments. The authors thank Rachel Aaron and Tiffany Tian (Diabetes Technology Society, Burlington, CA) for their editing assistance and Michael Bonar (Leicester Diabetes Centre, Leicester, U.K.) for figure design. Funding and Duality of Interest. G.E.U. is supported by research grants from the National Institutes of Health (NIH) (NATS UL 3UL1TR002378-0552) from the Clinical and Translational Science Award program and from the NIH and National Center for Research Resources (NIH/National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK] 2P30DK111024-06) and has served as a member of advisory boards for Dexcom and GlyCare. G.M.D. is supported by a research grant from NIH/NIDDK Career Development Award K23DK122199, has received research support from Insulet, and has consulted for Medscape. G.P.F. has received honoraria and consultancy and lecture fees from Abbott, AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Mundipharma, Sanofi, Takeda, and Servier. R.J.G. is supported by the NIDDK of the NIH under award numbers P30DK111024-08, 1K23DK123384, and 1R03DK138255. R.J.G. has also received research support (to Emory University) for studies from Novo Nordisk, Dexcom, and Eli Lilly and consulting/advisory or honoraria/lecture fees from Abbott Diabetes, Dexcom, Eli Lilly, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Medtronic, and Bayer outside of this work. I.B.H. has received research support from the NIH, Dexcom, and MannKind and serves as consultant for Abbott Diabetes Care, Embecta, and Hagan. D.C.K. is a consultant for Afon, Atropos Health, GlucoTrack, Lifecare, Nevro, Novo Nordisk, Samsung, and Thirdway. R.G.M. is supported by the NIDDK of the NIH (R03DK127010 and R01DK135515), the National Institute on Aging of the NIH (R01AG079113), the Patient-Centered Outcomes Research Institute (DB-2020C2-20306), and the American Diabetes Association. R.G.M. also serves as a consultant to EmmiEducation (Wolters Kluwer) on developing patient education materials related to diabetes and to Yale New Haven Health System’s Center for Outcomes Research and Evaluation on developing quality measures related to diabetes. S.M. holds a personal award from the Wellcome Trust Clinical Career Development Scheme (223024/Z/21/Z) and is supported by the National Institute for Health Research Imperial Biomedical Research Centre. S.M. also reports an investigator-initiated grant from Dexcom and has received speaker fees (donated to the institution) from Sanofi and Lilly. R.A.G. has served as a consultant to Lark, Vida, and Sweetch. R.R.B. and N.A.E. declare that there are no relationships or activities that might bias, or be perceived to bias, their work. K.K.D. has received honoraria for travel, advisory boards, and speaker fees from Abbott Diabetes, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Menarini, and Sanofi Diabetes. No other potential conflicts of interest relevant to this article were reported. Prior Presentation. Parts of this work were presented at the 59th EASD Annual Meeting, Hamburg, Germany, 2–6 October 2023; the AACE Annual Meeting, New Orleans, LA, 9–11 May 2024; and the ADA 84th Scientific Sessions, Orlando, FL, 21–24 June 2024.

References
46. Davis TME, Davis W. Incidence and associates of diabetic ketoacidosis in a community-based cohort: the Freemantle Diabetes Study Phase II. BMJ Open Diabetes Res Care 2020;8:e000983
55. Davis SN, Umpierrez GE. Diabetic ketoacidosis in type 2 diabetes mellitus—patho-
60. Jiang DH, Herrin J, Van Houten HK, McCoy RG. Evaluation of high-deductible health plans and acute glycemic complications among adults with diabetes. JAMA Netw Open 2023;6:e232502
73. Wessäli NH, Adolphsson F, Forsander G, Hansa R. Insulin pump therapy is associated with higher rates of mild diabetic ketoacidosis compared to injection therapy—a 2-year Swedish national survey of children and adolescents with type 1 diabetes. Pediatr Diabetes 2022;23:1038–1044
83. Yuen KCI, McDaniel PA, Riddle MC. Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action. Clin Endocrinol (Oxf) 2012;77:224–232
leads to prolonged management of diabetic ketoacidosis. Pol Arch Intern Med 2018;128: 416–420


163. Riveline JP, Roussel R, Vicaut E, et al. Reduced rate of acute diabetes events with flash glucose monitoring is sustained for 2 years after initiation: extended outcomes from the RELIEF study. Diabetes Technol Ther 2022;24:611–618


180. Chen IW, Lin CW. Improvement in renal prognosis with prompt hemodialysis in hyperosmolar hyperglycemic state-related rhabdomyolysis: a case report. Medicine (Baltimore) 2018; 97:e16647


